Indication
As monotherapy for the treatment of adults and adolescents 12 years and older with advanced rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC).
Medicine details
- Medicine name:
- selpercatinib (Retsevmo)
- SMC ID:
- SMC2732
- Pharmaceutical company
- Eli Lilly and Company Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- 09 June 2025
- Patient group submission deadline:
- 07 April 2025